Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

231.52
-0.8300-0.36%
Post-market: 227.76-3.7600-1.62%19:30 EDT
Volume:1.00M
Turnover:233.31M
Market Cap:15.03B
PE:15.83
High:236.00
Open:231.60
Low:230.39
Close:232.35
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.24
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.13
PE(LYR):-39.64

Loading ...

Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed

Simply Wall St.
·
Aug 13

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 12

Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says

MT Newswires Live
·
Aug 11

Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley

TIPRANKS
·
Aug 11

Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 11

Jazz Pharmaceuticals Buys Actio Biosciences for at Least $820 Million

MT Newswires Live
·
Aug 10

Jazz Bets on Epilepsy Treatment with up to $1.32 Billion Deal for Actio

Reuters
·
Aug 10

Jazz Pharmaceuticals - to Buy Actio Biosciences for $820 Mln Upfront, up to $500 Mln Contingent

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Actio Biosciences to Spin Out New Private Entity; Jazz to Receive Minority Stake

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - Deal Expected to Close by Q4 2026, Subject to Conditions

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

THOMSON REUTERS
·
Aug 10

Jazz Pharmaceuticals - to Fund Deal with Cash on Hand and Existing Financing Facilities

THOMSON REUTERS
·
Aug 10

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

UBS Adjusts Jazz Pharmaceuticals Price Target to $315 From $307, Maintains Buy Rating

MT Newswires Live
·
Aug 05

Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord

TIPRANKS
·
Aug 05

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Simply Wall St.
·
Aug 05

Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says

MT Newswires Live
·
Aug 04

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Benzinga Earnings
·
Aug 04

Jazz Pharmaceuticals is Maintained at Outperform by Baird

Dow Jones
·
Aug 04